Los Angeles Allergist

Los Angeles Allergist

Make an Appointment Online book-darkblue

  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

16260 Ventura Blvd., Suite 140
Encino, CA 91436
Phone: 818-528-7776

September 21, 2016 by Alan Khadavi

Anaphylaxis with Xolair, a Case Study

Anaphylaxis with Xolair is a rare occurrence, approximately 0.2%.  A recent study published in the Journal of Allergy and Clinical Immunology titled “Anaphylactic reactions associated with omalizumab administration: Analysis of a case-control study” looked to clarify the circumstances and risk factors associated with anaphylaxis to Xolair.

Xolair or omalizumab is indicated for moderate to severe persistent asthma and chronic idiopathic or chronic spontaneous urticaria.  After Xolair was approved, the US Food and Drug Administration advised including it in an updated US package insert warning of anaphylaxis with Xolair, although the risk is small, it is possible.

In the study published, anaphylaxis with Xolair occurred most frequently within the first 3 doses and within 1 hour of dosing.  In contrast, a previous analysis, a delay between the administration of Xolair (omalizumab) and the onset of anaphylaxis was observed.  This delay prompted the suggestion of prolonged in office observation times.  The reasons for this discrepancy between the two studies are not apparent.

What researchers can not figure out though, is the mechanism of action of anaphylaxis with Xolair (omalizumab).  There was no IgE mediated event found underlying anaphylactic episodes due to the administration of Xolair.  It has been hypothesized that they are due to a reaction to polysorbate, an excipient in the the preparation.

Although anaphylaxis with Xolair remains a rare event, when prescribing omalizumab, health care providers should consider these observations along with clinical benefits and should adhere to recommended clinical guidance regarding monitoring for anaphylaxis.

None of the anaphylactic episodes in the study resulted in disability or death.  Although 40% of them were considered life-threatening and 20% required hospitalization.  Treatment of the anaphylaxis included the use of antihistamines, epinephrine, systemic corticosteroids and inhaled Beta-agonists.

To read more about Xolair in our other blog posts, you can click below.  If you have any questions if Xolair is the right medication for you, contact your local allergist or allergy doctor.

Response of hives after treatment with Xolair

Peanut Desensitization using Xolair

 

Filed Under: Anaphylaxis, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

April 12, 2018

Vitamin E and Asthma, does it help?

vitamin E and asthma

March 29, 2018

Common Eczema Triggers

eczema triggers

March 28, 2018

IgG Food Testing

igg food testing

March 23, 2018

Lupin Allergy on the rise

lupin allergy

March 22, 2018

Adolescent Anaphylaxis-Adverse Food Reactions

adolescent anaphylaxis

March 19, 2018

Flying with Peanut Allergy, is it safe?

flying with peanut allergy

March 14, 2018

Asthma and Physical Activity

asthma and physical activity

March 8, 2018

Dupilumab for Asthma, a New Indication

dupilumab for asthma

March 7, 2018

Maternal Peanut Consumption while Breast-Feeding

maternal peanut consumption

February 21, 2018

Xhance for Nasal Polyps

xhance

Read More Posts...

Follow Us…

© 2018 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page